Marker Therapeutics, Inc.
MRKR
$1.19
$0.00030.03%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 113.14% | 647.67% | 53.30% | 0.79% | 39.18% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 113.14% | 647.67% | 53.30% | 0.79% | 39.18% |
| Cost of Revenue | 94.33% | 69.74% | -1.79% | -23.74% | 19.93% |
| Gross Profit | -81.60% | 13.55% | 27.80% | 37.87% | -9.68% |
| SG&A Expenses | -25.42% | -39.50% | -54.66% | -43.80% | -14.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 53.05% | 25.11% | -28.99% | -31.58% | 5.17% |
| Operating Income | -31.44% | 25.00% | 44.17% | 40.85% | 3.32% |
| Income Before Tax | -38.41% | 22.60% | 46.51% | 43.36% | 10.08% |
| Income Tax Expenses | 1,251.35% | -- | -- | -- | -- |
| Earnings from Continuing Operations | -40.05% | 22.60% | 46.51% | 43.36% | 9.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | 92.26% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -36.91% | 22.60% | -187.16% | 51.83% | 27.31% |
| EBIT | -31.44% | 25.00% | 44.17% | 40.85% | 3.32% |
| EBITDA | -- | -- | -- | -- | -0.67% |
| EPS Basic | -32.64% | 23.44% | -186.01% | 52.81% | 31.53% |
| Normalized Basic EPS | -34.04% | 23.44% | 47.22% | 44.52% | 11.99% |
| EPS Diluted | -32.64% | 23.53% | -188.72% | 52.60% | 31.53% |
| Normalized Diluted EPS | -34.04% | 23.44% | 47.22% | 44.52% | 11.99% |
| Average Basic Shares Outstanding | 3.23% | 1.10% | 1.35% | 2.08% | 6.17% |
| Average Diluted Shares Outstanding | 3.23% | 1.10% | 1.35% | 2.08% | 6.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |